November 25, 2016 - By Adrian Mccoy · 0 Comments
Mylan Inc (NASDAQ:MYL) institutional sentiment decreased to 0.33 in Q2 2016. Its down -0.12, from 0.45 in 2016Q1. The ratio worsened, as 5 investment professionals started new or increased equity positions, while 11 reduced and sold stock positions in Mylan Inc. The investment professionals in our partner’s database now have: 533,685 shares, down from 860,251 shares in 2016Q1. Also, the number of investment professionals holding Mylan Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 5 Increased: 4 New Position: 1.
Mylan N.V. is a global pharmaceutical company. The company has a market cap of $19.73 billion. The Firm develops, licenses, makes, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients . It has a 72.22 P/E ratio. It operates through two divisions: Generics and Specialty.
About 430,918 shares traded hands. Mylan NV (NASDAQ:MYL) has declined 23.69% since April 22, 2016 and is downtrending. It has underperformed by 29.10% the S&P500.
Analysts await Mylan NV (NASDAQ:MYL) to report earnings on February, 8. They expect $1.42 earnings per share, up 16.39% or $0.20 from last year’s $1.22 per share. MYL’s profit will be $759.88 million for 6.49 P/E if the $1.42 EPS becomes a reality. After $1.38 actual earnings per share reported by Mylan NV for the previous quarter, Wall Street now forecasts 2.90% EPS growth.
According to Zacks Investment Research, “Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.”
Princeton Portfolio Strategies Group Llc holds 1.89% of its portfolio in Mylan NV for 135,477 shares. Novare Capital Management Llc owns 79,851 shares or 0.93% of their US portfolio. Moreover, Westport Resources Management Inc has 0.37% invested in the company for 26,765 shares. The West Virginia-based Ntv Asset Management Llc has invested 0.26% in the stock. Covington Capital Management, a California-based fund reported 39,339 shares.#img1#
Ratings analysis reveals 63% of Mylan Inc.’s analysts are positive. Out of 16 Wall Street analysts rating Mylan Inc., 10 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. The lowest target is $46 while the high is $85. The stock’s average target of $59.67 is 61.84% above today’s ($36.87) share price. MYL was included in 28 notes of analysts from July 27, 2015. The company was maintained on Friday, November 18 by Mizuho. The rating was reinitiated by JP Morgan with “Overweight” on Wednesday, November 18. Morgan Stanley reinitiated Mylan NV (NASDAQ:MYL) on Thursday, December 3 with “Equal-Weight” rating. Mizuho initiated it with “Buy” rating and $49 target price in Wednesday, October 26 report. The rating was initiated by Barclays Capital with “Equal Weight” on Monday, September 21. The stock has “Buy” rating given by Deutsche Bank on Friday, August 7. Argus Research maintained Mylan NV (NASDAQ:MYL) on Friday, August 7 with “Buy” rating. The firm earned “Outperform” rating on Wednesday, May 4 by Leerink Swann. The rating was upgraded by Zacks to “Hold” on Thursday, August 27. The rating was initiated by Standpoint Research on Wednesday, August 26 with “Buy”.
Mylan N.V., incorporated on July 7, 2014, is a global pharmaceutical company. The Firm develops, licenses, makes, markets and distributes generic, branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). The Firm operates through two divisions: Generics and Specialty. The principal markets for Generics are pharmaceutical wholesalers and distributors; group purchasing organizations; drug store chains; independent pharmacies; drug manufacturers; institutions, and public and governmental agencies primarily within the United States and Canada (collectively, North America); Europe, and India, Australia, Japan, New Zealand and Brazil (collectively, Rest of World). The Generics segment also focuses on developing API with non-infringing processes for both internal use and to partner with manufacturers in regulated markets, such as the United States and the European Union at market formation. The principal market for Specialty is pharmaceutical wholesalers and distributors, pharmacies and healthcare institutions primarily in the United States.
More important recent Mylan NV (NASDAQ:MYL) news were published by: Profitconfidential.com which released: “Mylan NV: This Is Why MYL Stock Will Likely Continue to Drop” on November 07, 2016, also Investorplace.com published article titled: “Mylan NV (MYL) Stock Holders Can Shrug Off Kaleo’s EpiPen Threat”, Seekingalpha.com published: “Mylan NV (MYL) Q3 2016 Results – Earnings Call Transcript” on November 10, 2016. More interesting news about Mylan NV (NASDAQ:MYL) was released by: Businessinsider.com and their article: “EpiPen-maker Mylan whiffs on earnings” with publication date: November 09, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy